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The efficacy of the five-day plan to stop smok-
ing (FDP) has seldom been assessed in a country
such as Switzerland, whose level of tobacco 
control is still insufficient [1]. Furthermore, the
previous studies were performed before pharma-
cotherapy for smoking cessation, such as Nicotine
Replacement Therapy (NRT), was either available
or widely used [2–4].
For many years, Switzerland occupied the
sixth position in the world classification of ciga-
rette consumption: 35% of the population are
smokers. The highest proportion of smokers is
found among young adults aged 20 to 24, with
46% of men and 36% of women being smokers [5].
Furthermore, smoking also extends to younger age
groups: among 15-year-old schoolchildren, smok-
ing increased from 15% in 1986 to 25% in 1998
[6]. Smoking is also on the increase in the female
population [7, 8; press release]. Despite evidence
of morbidity during pregnancy, the proportion of
smokers among pregnant women increased from
15% in 1981 to 25% in 1995 [9, 10].
In Switzerland, 600,000 smokers try to give up
the habit every year but only 100,000 succeed [11].
The spontaneous success rate is 4% [12].
The aim of this study was to evaluate the long
term efficacy of the FDP in a Swiss population.
The “Five-Day Plan to Stop Smoking” (FDP)
is an educational group technique for smoking
cessation. We studied a cohort of 123 smokers 
(55 men, 68 women, mean age 42 years) who par-
ticipated in 11 successive FDP sessions held in
Switzerland between 1995 and 1998 and who were
followed up for at least 12 months by telephone or
direct interview. Overall, 102 of the 123 subjects
(83%) had stopped smoking by the end of the FDP,
and self-declared smoking cessation rate was 25%
after one year. The following factors potentially
associated with outcome were studied: age, sex,
smoking habit duration, cigarettes per day, Fager-
ström Test for Nicotine Dependance (FTND),
group size, and medical presence among the group
leaders. Smoking habit duration was the only vari-
able which showed a statistically significant asso-
ciation with success: the rate of smoking cessation
was higher among patients who had smoked for
less than 20 years (34.7% vs. 18.9%, p = 0.049).
Stress was the most common cause of relapse. The
FDP appears to be an effective smoking cessation
therapy. Propositions are made in order to im-
prove the success rate of future sessions.
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Introduction
Patients and methods
FDP
The FDP is a group method for smoking cessation
developed in the United States in the late fifties. The pro-
gram is led by a physician and a psychologist trained to
treat both the physiological and the psychological aspects
of smoking cessation. Their knowledge is updated annu-
ally by following the courses specific to the FDP.
Participants are volunteers who respond to an an-
nouncement in the local media. Information flyers are also
sent to former participants and to family doctors in the
area. No exclusion criteria are applied. The registration
fee is 100 Euros. Some health insurance companies par-
ticipate, but this is not systematic. A FDP session takes
place over 5 consecutive evenings, preceded by a prepara-
tory meeting the week before. Each meeting lasts about
90 minutes. Two further meetings are organized in order
to reinforce motivation, one after 2 weeks and the other
after 1 month. Further meetings are planned according to
the group’s wishes.
The first moderator, generally a doctor, provides in-
formation on public health, the neuro-endocrine effects of
nicotine on the brain, and the physiopathological effects
of smoke on the cardiovascular and pulmonary systems.
He / she also gives dietary advice in order to limit weight
gain. Emphasis is placed on the physiopathological aspects
of withdrawal symptoms and their reversibility.
Complete abstinence is proposed from the first meet-
ing onward and no nicotine substitution is proposed. Sub-
jects are referred to their family doctor for any medical
prescription.
On the psychological level, the FDP methodology is
based on educational, cognitive and behavioural work in
order to develop a non-smoker psychological approach.
The moderator reinforces motivation by suggesting ex-
ploration of possible conscious and unconscious influ-
ences [13]. Long-term cessation is obtained by stress man-
agement (i.e. physical exercise, relaxation, rest), avoidance
of high-risk situations and emphasis of the possible bene-
fits. Daily success rates of the group are shown to encour-
age each participant. Solidarity is reinforced by the
exchange of phone numbers (“buddy system” of mutual
reinforcement).
A diet is proposed for each day to facilitate with-
drawal, to correct possible dietary imbalance associated
with smoking and smoking cessation, and to increase
awareness of the risk of weight gain. For the first 24 hours
intake is restricted to water and fruits. During the week,
vegetables, cereals and dairy products are introduced suc-
cessively. This diet is adapted to specific cases such as di-
abetic patients or manual workers. Participants are advised
against alcohol and coffee consumption to avoid positive
reinforcement. Each meeting is followed by a snack based
on the dietary items to be added to the next day’s diet, and
personal contact between participants is possible at this
time.
Study
This study analysed 11 consecutive FDP sessions held
in Switzerland (Vaud canton, a French speaking part of 
the country) between May 1995 and February 1998. Each
participant filled out a questionnaire to collect data on age,
sex, smoking habit duration, cigarettes per day, and Fager-
ström Test for Nicotine Dependance (FTND) [14].
All participants were contacted by phone by one of
the moderators after 3, 6, 12 and 24 months. After 7 un-
successful attempts to make phone contact, the participant
was judged to be lost to follow-up and considered a fail-
ure. When the participant was absent only the partner was
considered to be a reliable source of information.
The smoking of even 1 cigarette was considered as 
a relapse.
Likelihood of cessation was analysed according to age
(≤40 years vs. >40 yr), sex, smoking habit duration (<20 yr
vs. ≥20 yr), cigarettes per day (≤20 cig/day vs. >20) and
FTND (≤4 vs. >4). Cutoff points were arbitrarily deter-
mined for dichotomization of these variables. The chosen
value for FTND is consistent with previous reports [15].
We used the Chi-square or Fisher’s Exact tests for the
comparison of categorical data, and T-test or Wilcoxon-
rank sum test for comparison of continuous data. A p-value
<.05 was considered as significant. We used logistic re-
gression analysis to adjust for potential confounders when
assessing the association between smoking abstinence and
the covariates mentioned above. Results are presented 
as odds-ratio (OR) with their 95% confidence intervals
(95% CI). Statistical analyses were performed with Stata
(Stata Corporation – College Station, Tx) software. For
smoking abstinence we performed an intention-to-treat
analysis and considered smokers lost to follow-up as 
continuing smokers.
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Results
The total number of participants studied was
123. Their baseline characteristics are shown in
table 1.
No patient received additional NRT during
FDP.
Five patients attended two FDP sessions. We
consider only the first one for the current analysis.
Seven participants dropped out before the fifth
meeting, representing 7 relapses. Six participants
were lost to follow-up. Even though four of these
did not resume smoking after the FDP sessions
they were considered as relapses after one month.
The smoking abstinence rates were the fol-
lowing: at the end of the session, 102 of the 123
participants (82.9%) had stopped smoking. Suc-
cess rates were 66.7% at 1 month, 48.8% at 3
months, 30.9% at 6 months and 25.2% after 1 year.
Likelihood of cessation according to age, sex,
smoking habit duration, cigarettes per day,
FTND, number of participants and medical pres-
ence are reported in table 2.
Smoking habit duration was found to be the
only statistically significant prognostic factor.
Rate of smoking cessation was higher among
patients who had smoked for less than 20 years
(34.7% vs. 18.9%, p = 0.049), and this association
was confirmed by multivariate analysis (OR 1.35
[1.11–2.27]).
Figure 1 shows the evolution of the cohort ac-
cording to smoking duration.
We did not find any relationship between the
increasing expertise of the moderators and success
rates (data not shown).
The main reason given for relapse was stress
for 44 participants (47.8%), lack of motivation for
17 (18.5%), social pressure for 15 (16.3%), de-
pression for 7 (7.6%), and weight gain for 3 (3.3%).
Mean age, years (range) 42 (18–71)
Male, % 44.7
Mean cigarette consumption / day (range) 25 (5–70)
Mean duration of smoking, years (range) 21.5 (1–53)
Mean Fagerström score (range) 6 (1–10)
Mean participants / session (range) 16 (4–27)
Table 1 
Baseline patients
characteristics 
(n = 123).
Our study shows that 25% of smokers attend-
ing FDP are abstinent at 1 year. During the first 3
months the proportion of relapses was high (56%)
but diminished after that. This observation is com-
parable with that already reported in the literature
[16, 17]. The success rate with FDP at one year in
our study population was comparable with that
obtained by techniques of smoking cessation using
nicotine substitution [18]. These results could be
improved by combined treatments [19].
The only variable which had a statistically sig-
nificant impact on long-term outcome was the
smoking habit duration: the long-term success rate
was greater in subjects who had smoked for less
than 20 years. Several hypothesis may be evoked
to explain this: a longer period of exposure to re-
inforcement mechanisms may render smoking ces-
sation more difficult; gestural habits may become
even more ingrained after a consumption of 20
years’ duration; lastly, there is the possibility that
a progressive change may occur in the functions of
nicotine-dependent receptors. 
The other prognostic factors considered (age,
sex, cigarette consumption, FTND, number of
participants in sessions and medical presence) were
not found to be associated with long-term success,
and their predictive value is in fact contested in the
literature [2, 20, 21].
The participants attributed the majority of re-
lapses to a state of stress, as described by the par-
ticipants. Irritability, agitation, difficulty in con-
centrating, frustration and nervous tension were
found to be the main outward manifestations of
this stress. These symptoms of nicotine withdrawal
on the central nervous system could have been at-
tenuated by giving a controlled amount of nico-
tine. This approach could also be useful in limit-
ing relapse due to the development of depression.
Unfortunately, the framework of the FDP does not
permit the individual detection of depressive ten-
dencies or latent anxiety as envisaged by the con-
sensus conference on smoking cessation in 1998
[6]. However, the doctor moderating the FDP ses-
sions emphasises the anti-depressive effect of nico-
tine and the risk of depression during cessation in
at-risk subjects [22, 23]. In case of doubt the par-
ticipant is encouraged to consult his family doctor
at an early stage. 
In the majority of studies fear of weight gain is
considered to be an obstacle to smoking cessation
[9]. In our experience this obstacle was the cause
of only a small proportion of relapses. This en-
couraging result was certainly due to the dietary
advice given and to the special diet proposed,
which constitute one of the major advantages of
the FDP.
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Discussion
n Success rate n Sucess rate p-value
after after
12 months 12 months
age ≤40 years 59 23.70% >40 years 64 26.60% 0.718
sex women 68 25.00% men 55 25.50% 0.954
smoking habit duration <20 years 49 34.70% ≥20 years 74 18.90% 0.049
cigarettes per day ≤20 cig/day 63 25.40% >20 cig/day 60 25.00% 0.96
6-item Fagerström score ≤4 32 18.80% >4 91 27.50% 0.328
number of participants ≤5 / session 8 25.00% >5 / session 115 25.20% 0.989
medical presence yes 100 26.00% no 23 21.70% 0.671
Table 2
Prognostic factors.
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Figure 1
Evolution according
to smoking habit
duration.
There have been relatively few studies on the
results of the FDP in Europe and the USA. To our
knowledge no such study has been carried out in
Switzerland.
Success rates at one year as reported in the
literature vary between 16% and 66% [2–4, 20,
24–30]. Patient selection methods, definition of
success and the statistical analysis methods used by
the different authors may explain these disparities.
The median success rate of all the studies was
28.15%, which corresponds to our results. A meta-
analysis has been carried out on the evaluation of
group behavioural methods [31]. Ten studies com-
pared a group programme and an individual pro-
gramme using the same information. They clearly
demonstrated the superiority of the group meth-
ods (OR 2.10 (95% Cl 1.64–2.70). In contrast,
when compared to medical or nurse counselling,
the group therapy methods did not influence the
chances of success. However, it should be noted
that there was a high degree of heterogeneity in
the methodology and in the results. 
Participation in FDP sessions implies a volun-
tary act by the smoker. Because the study popula-
tion was recruited via the FDP, participants may be
considered as being in the “preparation” phase ac-
cording to the classification method described by
Prochaska [32]. Therefore, our study population
cannot be considered to be representative of smok-
ers as a whole: in an unselected Swiss study popu-
lation, 73% of smokers were found to be in the
“precontemplation” phase when using the same
classification method [33]. On the other hand, in
view of the voluntary act described earlier, the
FDP population can be compared to subjects who
seek out the other therapeutic aids to smoking
cessation which are available to smokers.
An objective check of abstinence is one of the
problems inherent in the validation of a smoking
cessation method. The voluntary decision to
participate in the FDP and the psychological
approach of this method help to make the smoker
feel responsible for his/her smoking cessation, and
we thus decided not to confirm the smoking ces-
sation by measurement of CO or urinary cotinine
levels. We consider that the “confidence relation-
ship” built up between the session leaders and each
participant in the course of the five evening ses-
sions is such as to guarantee the veracity of the an-
swers to questioning during follow-up. Indeed, the
literature confirms the value of the replies given 
by participants in a smoking cessation therapy
method concerning their tobacco consumption
[34]. Nevertheless, the lack of an objective mea-
sure to verify the self-declared smoking status is a
clear limitation of this study.
Replication of the method was another prob-
lem met with in the evaluation of FDP, even
though it is considered to be the best codified be-
havioural therapy [35]. Many and diverse parame-
ters may influence the outcome of a session: the
session leaders, whose personality and experience
may condition the relationship which is estab-
lished with each participant; the size and compo-
sition of the groups; the socio-cultural context; 
and the local mentality may all play such a role. In
this study no attempt was made to compare one
session with another. The heterogeneous nature of
our study population permits a comparison of our
results with other studies published concerning the
FDP, as these also concern widely varying study
populations.
Conclusion
The success rate after one year was 25%. The
FDP offers global physiological and psychological
support, without medication or other treatments.
This result is in concordance with other pub-
lished results using this method. Comparison with
other recognized methods (nicotine substitution,
anti-depressants, behavioural therapies) showed
similar efficacy.
Smoking habit duration of less than 20 years
was the only statistically significant positive prog-
nostic factor.
Relapse occurred early and about half of all the
smokers mentioned stress as the relapse factor. On
the other hand, weight gain was seldom mentioned
as a factor of relapse.
In order to improve the results, individual
medical support on an out-patient basis should be
provided after treatment.
Further studies are needed to evaluate the ben-
efit of combining the FDP either with nicotine
substitution for patients with marked withdrawal
symptoms, or with anti-depressant treatment for
at-risk patients.
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